Sartorius Stedim Biotech
€208.20Change from previous close: +0.97%Absolute change: +€2.00
At a glance
- Revenue growth
- +6.74%
- 2025 vs 2024
- Net income growth
- +51.68%
- 2025 vs 2024
- Net margin
- 9.0%
- 2024: 6.3%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total revenue | 766 | 762 | 772 | 745 | 745 |
| Cost of revenue | 407 | 416 | 455 | 400 | 388 |
| Gross profit | 359 | 345 | 317 | 345 | 356 |
| Selling, general and administrative | 163 | 163 | 170 | 167 | 167 |
| Research and development | 35.3 | 38.4 | 31.7 | 32.1 | 39.2 |
| Operating income | 154 | 149 | 134 | 129 | 141 |
| EBIT | 161 | 166 | 71.6 | 129 | 179 |
| EBITDA | 240 | 247 | 156 | 207 | 256 |
| Interest expense | 34.2 | 46.5 | -6.2 | 36.3 | 63.3 |
| Pre-tax income | 127 | 119 | 77.8 | 92.6 | 115 |
| Income tax | 32.9 | 31.0 | 30.5 | 24.0 | 30.0 |
| Net income | 93.0 | 88.1 | — | 68.5 | 85.6 |
| Net income to common shareholders | 93.0 | 88.1 | 47.3 | 68.5 | 85.6 |
| Basic EPS | 0.96 | 0.91 | — | 0.70 | 0.88 |
| Diluted EPS | 0.96 | 0.91 | — | 0.70 | 0.88 |
| Average shares (basic) | 96.9 | 96.8 | — | 97.9 | 97.3 |
| Average shares (diluted) | 96.9 | 96.8 | — | 97.9 | 97.3 |